Sildenafil terminology spans several different areas, including pharmacokinetics, pharmacodynamics, pharmaceutical identity, regulatory naming and prescription access. Understanding which category a term belongs to helps prevent concepts with very different meanings from being treated as interchangeable.
Terms such as Tmax, Cmax, AUC, bioavailability and half-life describe concentration and exposure behavior, while PDE5, cGMP and pharmacodynamics relate to biological targets and drug effects. Brand names, generic names, dosage forms and regulatory terms describe the medicine from different product and approval perspectives.
This glossary provides concise definitions and navigation to deeper sildenafil pages. It is designed to identify and distinguish concepts rather than replace dedicated explanations of pharmacology, pharmacokinetics, safety, clinical use or prescription access.
Sildenafil terminology is easier to understand when terms are grouped by concept instead of treated as one undifferentiated vocabulary list.
Some terms describe the active drug, others describe its movement through the body or its biological effects, while another group describes pharmaceutical products, regulatory status and ways prescription medicines are obtained.
Context matters. A pharmacokinetic measurement such as Tmax does not mean the same thing as clinical onset, and a brand name does not identify a different active drug merely because the product has a separate commercial identity.
| Category | What It Describes | Examples |
|---|---|---|
| Pharmacokinetics (PK) | What happens to sildenafil in the body over time | Absorption, bioavailability, Tmax, Cmax, AUC, half-life, clearance |
| Pharmacodynamics (PD) | What sildenafil does at biological targets and downstream pathways | PDE5 inhibition, cGMP, mechanism of action |
| Product identity | How the active drug and pharmaceutical product are named or formulated | Sildenafil, sildenafil citrate, brand name, generic name, dosage form |
| Regulatory terminology | How products and comparisons are described in an approval framework | Bioequivalence, reference product, NDA, indication |
| Access terminology | How prescription medicines are evaluated, prescribed and dispensed | Prescription, telehealth, pharmacy fulfillment, refill, mail order |
Drug identity terminology distinguishes the active drug from its salt form, proprietary product names and generic products.
These distinctions are useful because sildenafil, sildenafil citrate, a brand name and a generic product can refer to related concepts without being identical terms.
| Term | Definition | Related Page |
|---|---|---|
| Sildenafil | Nonproprietary name of the active drug moiety; marketed products commonly contain sildenafil in the citrate salt form | What Is Sildenafil? |
| Sildenafil citrate | Citrate salt form of sildenafil used in pharmaceutical products | Sildenafil Citrate Explained |
| Active ingredient | Drug component responsible for the intended pharmacological activity of a medicine | Sildenafil Active Ingredient Overview |
| Brand name | Proprietary name assigned to a specific marketed medicine product | Sildenafil Brand Names |
| Generic name | Nonproprietary drug name used independently of a specific brand identity | Generic Sildenafil Explained |
| Generic sildenafil | Sildenafil-containing prescription product marketed primarily under the nonproprietary drug name rather than a proprietary brand | Generic Sildenafil |
Pharmacokinetics describes the time course of sildenafil in the body, including absorption, distribution, metabolism and elimination.
PK measurements characterize concentration and exposure. They should not automatically be interpreted as measurements of clinical response, onset or duration of effect.
| Term | Meaning | Deep Dive |
|---|---|---|
| Pharmacokinetics (PK) | Study of how drug concentrations change over time through absorption, distribution, metabolism and elimination | Sildenafil Pharmacokinetics |
| ADME | Abbreviation for absorption, distribution, metabolism and elimination | Sildenafil ADME and Pharmacokinetics |
| Tmax | Time at which the maximum observed plasma concentration is reached | Sildenafil Tmax Explained |
| Cmax | Maximum observed plasma concentration in a pharmacokinetic profile | Sildenafil Cmax Explained |
| AUC | Area under the concentration-time curve, used to characterize systemic drug exposure over time | Sildenafil AUC Explained |
| Half-life | Pharmacokinetic parameter describing the rate at which drug concentration declines during an elimination phase | Sildenafil Half-Life |
| Clearance | Pharmacokinetic measure describing the efficiency with which drug is removed from systemic circulation | Sildenafil Clearance |
| Concentration-time curve | Graph showing how measured drug concentration changes across time after administration | Sildenafil Concentration-Time Curve |
Absorption describes entry of sildenafil into systemic circulation after administration, while distribution describes how the drug subsequently moves between blood and tissues.
Related measurements such as bioavailability, volume of distribution and protein binding describe different parts of this process and should not be treated as synonyms.
| Term | Definition | Related Page |
|---|---|---|
| Absorption | Process by which sildenafil enters systemic circulation after administration | Sildenafil Absorption |
| Bioavailability | Fraction of an administered dose that reaches systemic circulation as unchanged drug | Sildenafil Bioavailability |
| Distribution | Movement of sildenafil between systemic circulation and body tissues | Sildenafil Distribution |
| Volume of distribution | Apparent PK volume relating the amount of drug in the body to its measured plasma concentration | Sildenafil Volume of Distribution |
| Protein binding | Association of circulating drug molecules with plasma proteins | Sildenafil Protein Binding and Distribution |
| Exposure | Extent and pattern of systemic drug concentrations over time, commonly interpreted using measurements such as AUC and Cmax | Sildenafil Exposure |
Metabolism, excretion, clearance and half-life are related to drug removal but describe different processes or pharmacokinetic measurements.
Sildenafil is metabolized predominantly through hepatic CYP3A pathways, with CYP2C9 representing a minor pathway, and it forms metabolites including the pharmacologically active N-desmethyl metabolite.
| Term | Definition | Related Page |
|---|---|---|
| Metabolism | Enzymatic chemical transformation of sildenafil into metabolites | Sildenafil Metabolism |
| CYP3A4 | Important CYP3A enzyme involved in the major metabolic pathway for sildenafil | Sildenafil and CYP3A4 |
| CYP2C9 | Cytochrome P450 enzyme involved as a minor pathway in sildenafil metabolism | Sildenafil Metabolic Pathways |
| Active metabolite | Metabolite that retains pharmacological activity; sildenafil has a major circulating N-desmethyl metabolite | Sildenafil Active Metabolite |
| Elimination | Overall process by which sildenafil and its metabolites are removed from the body | Sildenafil Elimination and Clearance |
| Excretion | Removal of drug-related material from the body after administration, including excretion of metabolites | Sildenafil Excretion and Clearance |
| Clearance | PK parameter describing the body's overall efficiency in eliminating drug from systemic circulation | Sildenafil Clearance Explained |
Pharmacodynamics describes the biological actions and effects of sildenafil, including interaction with its molecular target and the signaling changes that follow.
Concentration-effect relationships can be part of pharmacodynamic analysis, but pharmacodynamics is broader than a single relationship between plasma concentration and response.
| Term | Definition | Related Page |
|---|---|---|
| Pharmacodynamics | Study of a drug's biological effects, mechanisms and relationships between drug exposure and response | Sildenafil Pharmacodynamics |
| PDE5 inhibition | Reduction of phosphodiesterase type 5 enzymatic activity by sildenafil | Sildenafil PDE5 Inhibition |
| NO-cGMP pathway | Signaling pathway in which nitric oxide promotes formation of cyclic GMP and PDE5 contributes to cGMP breakdown | Sildenafil and the NO-cGMP Pathway |
| Mechanism of action | Sequence of molecular and physiological events through which sildenafil produces its pharmacological effects | How Sildenafil Works |
| Drug target | Biological molecule whose activity is directly affected by a drug; PDE5 is the principal pharmacological target associated with sildenafil's intended mechanism | Sildenafil's PDE5 Target |
PDE5-related vocabulary describes the molecular target and signaling pathway central to sildenafil pharmacology.
These terms belong to mechanism and pharmacodynamics rather than product branding, prescription access or pharmacokinetic timing.
| Term | Definition |
|---|---|
| PDE5 | Phosphodiesterase type 5, an enzyme that hydrolyzes cyclic GMP and is inhibited by sildenafil |
| PDE5 inhibitor | Drug that reduces PDE5 enzymatic activity; sildenafil belongs to this pharmacological class |
| cGMP | Cyclic guanosine monophosphate, an intracellular signaling molecule regulated in part through synthesis and phosphodiesterase-mediated breakdown |
| Nitric oxide (NO) | Signaling molecule that can activate soluble guanylate cyclase and increase cGMP production |
| Guanylate cyclase | Enzyme activated by nitric oxide that catalyzes formation of cGMP |
| NO-cGMP signaling | Biological signaling sequence linking nitric oxide, guanylate cyclase, cGMP and downstream smooth-muscle responses |
Timing terminology is frequently misunderstood because pharmacokinetic timing and observed clinical timing answer different questions.
Tmax, onset, duration and half-life therefore should not be treated as interchangeable measurements or used as direct substitutes for one another.
| Term | Meaning | Related Page |
|---|---|---|
| Onset | Beginning of an observable clinical effect rather than the time of maximum plasma concentration | Sildenafil Onset |
| Duration | Period over which a clinically relevant effect may persist, distinct from the drug's pharmacokinetic half-life | Sildenafil Duration |
| Tmax | Time at which peak observed plasma concentration is reached | Sildenafil Tmax |
| Half-life | Pharmacokinetic concentration-decline parameter rather than a direct measurement of the clinical effect window | Sildenafil Half-Life |
Bioequivalence terminology is used in regulatory comparisons between pharmaceutical products and should not be reduced to the idea that two products are chemically identical in every respect.
PK measures such as AUC and Cmax are commonly used to compare systemic exposure, while the precise approval and equivalence requirements depend on the applicable regulatory framework.
| Term | Definition | Related Page |
|---|---|---|
| Bioequivalence | Regulatory comparison evaluating whether the rate and extent of drug exposure are sufficiently similar under predefined criteria | Sildenafil Bioequivalence |
| Generic drug | Medicine marketed under a nonproprietary name and subject to applicable regulatory requirements for approval | Generic Sildenafil |
| Generic equivalent | Generic product evaluated against an appropriate reference product under the relevant regulatory framework | Generic Sildenafil Equivalence |
| Reference product | Regulator-designated or otherwise specified comparator against which another pharmaceutical product is evaluated | Reference Products and Bioequivalence |
| Pharmaceutical equivalence | Regulatory concept concerning specified similarities between drug products, distinct from demonstrating comparable systemic exposure | Pharmaceutical Equivalence Explained |
| AUC in bioequivalence | PK measurement used to compare the extent of systemic exposure between products | Sildenafil AUC |
| Cmax in bioequivalence | PK measurement used to compare peak systemic concentration between products | Sildenafil Cmax |
Formulation terminology describes the physical pharmaceutical form and composition through which sildenafil is supplied.
Dosage form is separate from active ingredient identity: products can contain the same active drug while differing in formulation, route of administration, labeling or intended use.
| Term | Definition |
|---|---|
| Formulation | Combination and physical presentation of active and inactive components used to create a medicine product |
| Dosage form | Physical form in which a medicine is supplied and administered |
| Tablet | Solid dosage form intended for administration by the specified route, commonly oral in sildenafil products |
| Oral suspension | Liquid dosage form in which drug-containing material is dispersed in a liquid vehicle for oral administration |
| Injection | Parenteral dosage form intended for administration by injection rather than through the gastrointestinal tract |
| Route of administration | Path by which a medicine is introduced into the body, such as oral or intravenous administration |
Brand and regulatory terminology describes how individual sildenafil-containing products are identified, labeled and authorized.
A shared active drug does not mean that every branded or generic product has the same labeled indication, dosage form or product-specific instructions.
| Term | Meaning | Related Page |
|---|---|---|
| Viagra | Brand name for a sildenafil citrate tablet product labeled for erectile dysfunction | Viagra and Sildenafil Brand Names |
| Revatio | Brand name for sildenafil products labeled for pulmonary arterial hypertension | Revatio and Sildenafil Brand Names |
| Proprietary name | Regulatory and pharmaceutical term for a product-specific brand or trade name | Sildenafil Proprietary and Brand Names |
| NDA | New Drug Application, an application submitted to the FDA seeking authorization to market a specific new drug product in the United States | Sildenafil FDA Approval History |
| FDA approval | FDA authorization of a particular drug product for the uses and conditions described in its approved labeling | Sildenafil FDA Approval |
| Indication | Disease, condition or clinical use for which a drug product is described in its approved labeling | Sildenafil Approval and Indications |
| Labeling | Regulatory information accompanying an approved drug product, including indications, warnings, administration information and other product-specific details | Sildenafil FDA Labeling Context |
Access terminology describes the healthcare and pharmacy processes involved in obtaining a prescription medicine. These terms concern evaluation, prescribing and dispensing rather than sildenafil pharmacology.
Online access does not eliminate the distinction between clinical evaluation and pharmacy fulfillment: a healthcare professional may evaluate and prescribe, while a pharmacy performs dispensing and related fulfillment functions.
| Term | Definition | Related Page |
|---|---|---|
| Prescription | Authorization from an appropriately licensed prescriber for a prescription medicine | Sildenafil Online Prescription |
| Prescription access | Process through which a patient receives appropriate clinical evaluation and, when indicated, a valid prescription | How Sildenafil Prescription Access Works |
| Prescriber | Healthcare professional legally authorized within the applicable jurisdiction to prescribe medicines | Sildenafil Online Doctor |
| Telehealth | Delivery of healthcare services through remote communication technologies | Sildenafil Telehealth |
| Online pharmacy | Pharmacy service that allows eligible pharmacy transactions or fulfillment processes to be conducted online | Sildenafil Online Pharmacy |
| Pharmacy fulfillment | Pharmacy process of reviewing, preparing, dispensing and supplying a prescribed medicine | Sildenafil Pharmacy Fulfillment |
| Mail order | Pharmacy fulfillment model in which dispensed medicines are shipped to the recipient | Sildenafil Mail Order |
| Refill | Additional dispensing of a prescription when authorized under the prescription and applicable rules | Sildenafil Refill Online |
| Insurance coverage | Extent to which a health insurance or pharmacy benefit plan contributes to eligible prescription costs under its terms | Sildenafil Insurance Coverage |
Many sildenafil questions arise from combining terms that describe different stages, measurements or levels of pharmaceutical identity.
Separating drug identity, PK measurements, pharmacodynamic mechanisms, clinical timing and regulatory product terminology prevents a technical term from being given a meaning it does not actually have.
| Confused Terms | Difference |
|---|---|
| Sildenafil vs sildenafil citrate | Active drug moiety versus the citrate salt form used in pharmaceutical products |
| Sildenafil vs a brand name | Nonproprietary active-drug name versus the proprietary identity of a particular product |
| Brand vs generic | Proprietary product naming versus nonproprietary drug naming and generic product status |
| PK vs PD | Drug concentration and disposition over time versus biological actions and effects |
| Absorption vs bioavailability | Process of entering systemic circulation versus the fraction of a dose that reaches systemic circulation as unchanged drug |
| Tmax vs onset | Time of peak measured plasma concentration versus beginning of an observed clinical effect |
| Cmax vs AUC | Maximum observed concentration versus integrated systemic exposure over time |
| Half-life vs duration | PK concentration-decline parameter versus clinical effect window |
| Metabolism vs clearance | Chemical transformation of drug versus an overall PK measure of drug removal from circulation |
| Bioequivalence vs identical formulation | Regulatory comparison of product performance and exposure versus having exactly the same complete formulation |
| Same active ingredient vs same indication | Products can contain sildenafil while having different product-specific labeling, formulations or approved uses |
PK means pharmacokinetics. It describes how sildenafil concentrations change over time through processes including absorption, distribution, metabolism and elimination.
PD means pharmacodynamics. It describes sildenafil's biological actions and effects, including interaction with PDE5 and downstream signaling.
ADME stands for absorption, distribution, metabolism and elimination, four processes commonly used to organize pharmacokinetic concepts.
No. Tmax is the time at which the maximum observed plasma concentration is reached, while onset refers to the beginning of an observable clinical effect.
No. Half-life is a pharmacokinetic concentration-decline parameter, while duration refers to the period over which a clinically relevant effect may persist.
Sildenafil refers to the active drug moiety, while sildenafil citrate is the citrate salt form used in pharmaceutical products.
No. Sildenafil is the nonproprietary drug name, while Viagra is a proprietary brand name for a sildenafil citrate product.
Cmax is the maximum observed plasma concentration measured during a pharmacokinetic concentration-time profile.
AUC means area under the concentration-time curve and is used to characterize systemic drug exposure over a defined period.
No. Bioequivalence concerns whether specified measures of drug exposure are sufficiently similar under regulatory criteria; it does not mean every component of two formulations must be identical.
Telehealth refers to healthcare delivered remotely, while pharmacy fulfillment refers to the process by which a pharmacy prepares and dispenses a prescribed medicine.